Contributions
Abstract: PB2011
Type: Publication Only
Background
Prevalence of cluster of differentiation 20 (CD20) in classical Hodgkin Lymphoma (cHL) has been reported to range from 10-20%. However, the prognostic impact of such expression has been variable in the literature. Earlier reports indicated improved progression free survival (PFS) and overall survival (OS) (Tzankov et al., 2003) but such findings were later refuted where it was found to confer an adverse outcome (Portlock et al., 2004).
Aims
The aim of this study is to examine the prevalence and prognostic impact of CD20 expression in cHL in a patient population from the Middle East and North Africa Region (MENA).
Methods
After due IRB approval, patients diagnosed with cHL who received frontline therapy at our institution from 2008 – 2016 were identified and included for further analysis. All variables were retrospectively extracted. CD20 expression of 10% or higher was considered positive. Patients with nodular lymphocyte predominant HL were excluded. Cohorts were stratified per expression of CD20 and compared using Chi-squared and Wilcoxon tests, as appropriate. PFS was defined as time from diagnosis until progression or death due to any cause. Time to end point analysis was performed with the method of Kaplan and Meier with log ranks. Statistical analysis was computed using JMP software.
Results
A total of 199 patients were identified and included for further analysis. Prevalence of CD20 expression was noted in 41 (20.6%) of patients. The cohort was subsequently stratified per CD20 expression. Baseline age, stage, chemotherapy and radiotherapy delivered was similar between the strata. The monoclonal antibody Rituximab was used more frequently in those with CD20 expression (34% vs. 0.6%; p < 0.0001). There was also a trend of significance for higher proportion of male gender in the CD20 expressing cohort (34% vs. 0.6%; p < 0.0001). The estimated 2 year PFS was 71.2% vs. 69.5% for CD20 positive and negative, respectively (p = 0.52). The estimated 2 year OS for those with or without CD20 expression was 87.4% and 90.8%, respectively (p = 0.96).
Conclusion
We observed a comparable prevalence of CD20 expression in patients from the MENA region with cHL. However, in contrary to reported literature, CD20 expression did not confer an altered prognosis. It is possible that such expression is rendered insignificant in the contemporary era of therapy.
Session topic: 17. Hodgkin lymphoma – Clinical
Keyword(s): CD20, Hodgkin's Lymphoma, Rituximab
Abstract: PB2011
Type: Publication Only
Background
Prevalence of cluster of differentiation 20 (CD20) in classical Hodgkin Lymphoma (cHL) has been reported to range from 10-20%. However, the prognostic impact of such expression has been variable in the literature. Earlier reports indicated improved progression free survival (PFS) and overall survival (OS) (Tzankov et al., 2003) but such findings were later refuted where it was found to confer an adverse outcome (Portlock et al., 2004).
Aims
The aim of this study is to examine the prevalence and prognostic impact of CD20 expression in cHL in a patient population from the Middle East and North Africa Region (MENA).
Methods
After due IRB approval, patients diagnosed with cHL who received frontline therapy at our institution from 2008 – 2016 were identified and included for further analysis. All variables were retrospectively extracted. CD20 expression of 10% or higher was considered positive. Patients with nodular lymphocyte predominant HL were excluded. Cohorts were stratified per expression of CD20 and compared using Chi-squared and Wilcoxon tests, as appropriate. PFS was defined as time from diagnosis until progression or death due to any cause. Time to end point analysis was performed with the method of Kaplan and Meier with log ranks. Statistical analysis was computed using JMP software.
Results
A total of 199 patients were identified and included for further analysis. Prevalence of CD20 expression was noted in 41 (20.6%) of patients. The cohort was subsequently stratified per CD20 expression. Baseline age, stage, chemotherapy and radiotherapy delivered was similar between the strata. The monoclonal antibody Rituximab was used more frequently in those with CD20 expression (34% vs. 0.6%; p < 0.0001). There was also a trend of significance for higher proportion of male gender in the CD20 expressing cohort (34% vs. 0.6%; p < 0.0001). The estimated 2 year PFS was 71.2% vs. 69.5% for CD20 positive and negative, respectively (p = 0.52). The estimated 2 year OS for those with or without CD20 expression was 87.4% and 90.8%, respectively (p = 0.96).
Conclusion
We observed a comparable prevalence of CD20 expression in patients from the MENA region with cHL. However, in contrary to reported literature, CD20 expression did not confer an altered prognosis. It is possible that such expression is rendered insignificant in the contemporary era of therapy.
Session topic: 17. Hodgkin lymphoma – Clinical
Keyword(s): CD20, Hodgkin's Lymphoma, Rituximab